Clinical Trial Update: Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)

View source ↗

Summary

An update on a trial evaluating durvalumab after concurrent chemoradiotherapy in limited-stage small-cell lung cancer, with the study status shown as completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Anhui Shi, MD | Conditions: Small-cell Lung Cancer | Status: COMPLETED